Cyclosporine a inhibits tPA mRNA transcription in A431 cell line

Skin Pharmacology and Physiology

Volumn 9, Issue 2, 1996, Pages 137-140

  Teofoli, P ^a   Mancini, A ^b   Lotti, T ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Cyclosporine A; Keratinocytes; Psoriasis; Tissue type plasminogen activator mRNA

Indexed keywords

CYCLOSPORIN A; MESSENGER RNA; PLASMINOGEN; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KERATINOCYTE; NORTHERN BLOTTING; PRIORITY JOURNAL; PSORIASIS; RNA TRANSCRIPTION;

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMINOGEN; PSORIASIS; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED;

EID: 0029988442     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000211410     Document Type: Article

References (23)

1. Jefferey JR: Cyclosporine analogues. Clin Biochem 1991:24:15-22.
2. Kahan BD: Cyclosporine: A powerful addition to the immunosuppressive armamentarium. Am J Kidney Dis 1984:3:444-445.
3. Graffenried BV, Krupp P: Side effects of cyclosporine (Sandimmun in renal transplant recipients and in patients with autoimmune disease). Transplant Proc 1986;17:876-883.
4. Gottlieb AB: Immunologic mechanism in psoriasis. J Invest Dermatol 1990;95(suppl 5): 18S-19S.
5. Baadsgaard O, Fisher G, Voorhees JJ: The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990;95:S5,32S-33S.
6. Dano K, Andreasen PA, Grondahl-Hansen J. Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
7. Lotti T, Bonan P, Panconesi E: Plasminogen activation in psoriasis. Acta Derm Vencreol (Stockh) 1989(suppl 146):36-38.
8. Grondahl-Hansen J, Ralfldaer E, Nielsen LS, Kristensen P, Frcntz G, Dano K: Immunohistochcmical localization of urokinase and tissue type plasminogen activators in psoriatic skin. J Invest Dermatol 1987; 88:28-32.
9. Baird J, Lazarus GS, Belin D, Vas-salli DJ, Buss N, Gubler P, Jensen PJ: mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. J Invest Dermatol 1990; 95:548.
10. Jensen PJ, John M, Baird J: Urokinase and tissue type plasminogen in kératinocyte culture. Exp Cell Res 1990;187:162-169.
11. Hashimoto K, Wun TC, Baird J, Lazarus GS, Jensen PJ: Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 1989;92:310-314.
12. Fisher GJ, Duell EA, Nickoloff BJ, Anncsley TM, Kowalke JK, Ellis CN, Voorhees JJ: Levels of cyclosporine in epidermis of treated psoriasis patients differentially inhibit growth of kératinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988;91: 142-146.
13. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phe-nol-chlorophorm extraction. Anal Biochem 1987;162:156-159.
14. Mueller W, Herrmann B: Cyclosporin A for psoriasis. N Engl J Med 1979:301:555.
15. Harper JI, Keat ACS, Staughton RCD: Cyclosporine for psoriasis. Lancet 1984;ii:981-982.
16. Granelli-Piperno A, Inaba K, Stein-man RM: Stimulation of lvmpho-kine mRNA levels in stimulated human T cells: Kinetics, mitogen requirements, and effects of cyclosporine A. J Exp Med 1986; 163:922-937.
17. Siekeirka JJ, Humg SHY, Poe M, Shirley Lin C, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but it is distinct from cyclophillin. Nature 1989;341: 755-757.
18. Harding MW, Galat A, Uchling DE, Schreiber SL: Receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-760.
19. Granelli-Piperno A: In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of Cyclosporin A. J Exp Med 1988: 168:1649-1658.
20. Granelli-Piperno A: Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med 1990; 171:533-544.
21. Kanitakis J, Thivolet J: Cyclosporine. An immunosuppressant affecting epithelial cell proliferation. Arch Dermatol 1990;126:369-374.
22. Furue M, Gaspary AA, Katz SI: The effect of cyclosporin A on epidermal cells. II. Cyclosporin A inhibits proliferation of normal and transformed keratinocytes. J Invest Dermatol 1988:90:6,796-800.
23. Lotti T, Bonan P, Panconesi E: Epidermal plasminogen activator activity tPA dependent, is a marker of disease activity in psoriasis. J Invest Dermatol 1988;90:86-87.